Adrenocortical Carcinoma Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Rising Adoption of Precision Oncology for Rare Endocrine Cancers

Molecularly guided treatment selection is increasingly replacing uniform therapeutic approaches in the adrenocortical carcinoma treatment market. IGF2 overexpression occurs in nearly 90% of tumors, while disruptions in the Wnt and β-catenin pathways occur in up to 54% of cases, providing researchers with recurring targets in a disease historically treated with more uniform strategies. A 2025 study published in npj Precision Oncology found that more than 70% of high-SIS patients were predicted to respond to immune checkpoint blockade, whereas more than 65% of low-SIS patients were identified as biologically resistant.^{[1]W. Hao, “Multi-modal Characterization of Metabolic and Immune Gene Clusters in Adrenocortical Carcinoma Treatment,” npj Precision Oncology, NATURE.COM.} This distinction is significant because it can help reduce avoidable clinical trial failures in a disease with a limited patient population. Consequently, the adrenocortical carcinoma treatment market is increasingly favoring developers that align therapy design with companion diagnostics and more precise patient enrollment.

Expansion of Orphan Drug Development and Regulatory Incentives

Orphan drug policy support continues to benefit the adrenocortical carcinoma treatment market, as trial economics for this disease remain challenging without market exclusivity and development incentives. In the United States and Europe, orphan drug frameworks reduce commercial risk for sponsors that may otherwise struggle to justify Phase 2 development in an indication with a very low annual incidence. Public registries reflect this support, with small and mid-sized programs continuing to advance in rare endocrine oncology despite limited patient enrollment pools. Similarly, investigator-led advanced adrenocortical carcinoma studies continue in national multicenter settings, which would be difficult to sustain without regulatory and procedural support. These factors have expanded the number of companies willing to enter the adrenocortical carcinoma treatment market, even before new products receive approval.

Higher Use of Multimodal Therapy in Advanced and Metastatic Disease

Longer and more complex treatment pathways for patients with advanced disease support the adrenocortical carcinoma treatment market. The FIRM-ACT standard EDP-M regimen demonstrated a 23% objective response rate and a median overall survival of 14.8 months, while retrospective studies reported disease control rates ranging from 30% to 50%.^{[2]N. P. Rowell, “Oncological Management of Adrenocortical Carcinoma, An Update and Critical Review,” Oncology and Therapy, LINK.SPRINGER.COM.} However, optimizing mitotane therapy remains challenging because its induction of CYP3A4 can reduce etoposide exposure by nearly 50%, creating uncertainty around real-world treatment outcomes. Radiotherapy is also becoming increasingly relevant, as a 2025 meta-analysis involving 1,338 patients reported lower locoregional recurrence and mortality in higher-risk patients receiving postoperative radiation therapy. These trends support market growth as patients progress through surgery, systemic therapy, radiation therapy, and later-line management rather than relying on a single treatment modality.

Genomic Profiling Revealing Actionable Subsets for Trial Enrollment

Genomic testing is enabling faster, more targeted patient enrollment in clinical trials, thereby shaping the adrenocortical carcinoma treatment market. A prospective study planned for 2025 across UK and Italian cohorts aims to validate a 10-gene targeted panel comprising CTNNB1, TP53, ZNRF3, RB1, MEN1, CDK4, NF1, ATM, APC, and the TERT promoter. The panel uses variant allele frequency thresholds of 5% to 10%, aligning with real-world diagnostic timelines. This approach can help identify eligible patients near the time of surgery, rather than after they are lost within fragmented referral pathways. The importance of this shift was underscored by the Phase 2 pembrolizumab-plus-mitotane study at MD Anderson, which closed in July 2024 after enrolling only three patients. Companies and treatment centers that establish genomic registries before initiating larger combination trials may gain a practical advantage in the adrenocortical carcinoma treatment market.

Very Small Patient Pool Limiting Trial Scale and Commercial Uptake

Low disease incidence, generally estimated at 1 to 2 cases per million people annually, continues to constrain the adrenocortical carcinoma treatment market. Small patient populations not only hinder clinical trial enrollment but also limit the commercial potential available after product launch. This challenge was evident in the MD Anderson study of pembrolizumab plus mitotane, which concluded after enrolling only three patients despite a strong clinical rationale for the combination. The limited patient pool also requires developers to recover research costs across a narrow treated population, potentially complicating pricing and reimbursement in healthcare systems that lack clear rare-disease funding pathways. Consequently, the adrenocortical carcinoma treatment market continues to rely heavily on a limited number of tertiary care centers that can consistently identify, refer, and treat patients.

Severe Toxicity and Monitoring Burden of Current Systemic Therapies

Mitotane use in routine clinical practice creates a significant management burden for the adrenocortical carcinoma treatment market. Mitotane requires plasma concentrations of 14–20 mg/L, and a 2024 audit at a tertiary center in Ireland reported a median of seven months to achieve this therapeutic range. The audit also found abnormal thyroid function in 83% of patients and nausea in 67%, highlighting the complexity of routine management even in specialist settings.^{[3]“Management and Outcomes of Patients Treated with Mitotane for Adrenocortical Carcinoma in a Tertiary Adrenal Tumour Centre in Ireland,” Endocrine Abstracts, ENDOCRINE-ABSTRACTS.ORG.} Label and product information updates in North America and Europe continue to emphasize the risk of CYP3A4 interactions, affecting both current treatment practices and the design of combination-regimen clinical trials. These factors keep a significant share of the adrenocortical carcinoma treatment market within hospital settings and limit broader adoption in outpatient care.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Adrenocortical Carcinoma Treatment Market Segment Analysis

Surgery is projected to lead treatment revenue in the adrenocortical carcinoma treatment market, with a 41.30% share in 2025, as it remains the only curative option for localized disease. Open adrenalectomy continues to dominate clinical practice, while laparoscopic surgery is limited to selected tumors measuring less than 6 cm without local invasion. This limitation concentrates procedure volumes in high-volume centers. Chemotherapy remains the next most important treatment pillar, primarily through etoposide, doxorubicin, and cisplatin combined with mitotane (EDP-M). However, mitotane's effect on etoposide exposure continues to complicate dose planning and treatment consistency. Radiation therapy holds a smaller share, although recent evidence has strengthened its role as an adjunct therapy for locoregional control and selected metastatic settings.

Targeted therapy is projected to register the fastest CAGR of 7.23% in the adrenocortical carcinoma treatment market through 2031, as new combination therapies demonstrate greater activity than older single-agent approaches. The CaboACC Phase II dataset reported a 78% disease control rate, an 11% objective response rate, and a median progression-free survival of 6 months for cabozantinib in advanced ACC. The camrelizumab-apatanib combination also demonstrated notable outcomes, with an objective response rate of nearly 50% and a median progression-free survival of 12.6 months. These findings support dual VEGFR and PD-1 targeting over checkpoint monotherapy.^{[4]Declan Moore, “Therapeutic Strategies for Adrenocortical Carcinoma, Integrating Genomic Insights, Molecular Targeting, and Immunotherapy,” Frontiers in Immunology, FRONTIERSIN.ORG.} Within the adrenocortical carcinoma treatment industry, these developments indicate that future value creation will likely stem from combination-based targeted regimens rather than the incremental use of older cytotoxic backbones.

Localized disease is projected to account for 55.18% of revenue in the adrenocortical carcinoma treatment market in 2025, as most newly diagnosed patients enter treatment through surgery and adjuvant planning. The use of adjuvant mitotane in this setting is becoming more selective, particularly following evidence from the ADIUVO trial showing no benefit from two years of adjuvant treatment in low- to intermediate-risk patients. However, pooled analyses continue to support its benefit in higher-risk disease. This shift is expected to reduce treatment use among lower-risk patients while concentrating systemic therapy spending on patients with a higher risk of recurrence. Locally advanced disease represents a smaller segment; however, neoadjuvant EDP-M is gaining importance for borderline-resectable disease, where tumor shrinkage may enable surgical intervention.

The metastatic disease segment is projected to expand at a CAGR of 7.54% in the adrenocortical carcinoma treatment market through 2031, as patients typically require multiple lines of treatment and incur higher cumulative drug utilization. This segment includes systemic therapies, local control procedures, salvage treatments, and enrollment in clinical studies, resulting in higher revenue per patient than earlier-stage disease management. The planned opening of the CLARITY study in April 2026 and the Phase 1 DS9051b trial, expected to be recruiting by February 2026, indicate that later-line treatment options for metastatic disease are likely to expand. Consequently, within the adrenocortical carcinoma treatment industry, metastatic care is expected to contribute a disproportionate share of incremental revenue despite the limited patient population.

Hospitals are projected to account for 58.97% of revenue in the adrenocortical carcinoma treatment market in 2025, as they typically manage surgery, endocrinology, oncology, and therapeutic drug monitoring within a single institution. The infrastructure required for cortisol management, open adrenalectomy, adverse-event follow-up, and mitotane level testing further reinforces this concentration. Research and academic institutions also play an important role, particularly as early-stage programs, such as DS9051b and CY-101, are conducted through academic and specialist trial sites in Europe. Ambulatory surgical centers and home healthcare providers continue to hold smaller shares, as treatment complexity limits the extent to which care can shift away from specialist supervision.

Specialty clinics are forecast to grow at a CAGR of 7.84% through 2031, as stable patients transition to endocrine oncology follow-up outside major hospital outpatient units. This shift does not necessarily reduce revenue, as long-term management often involves drug titration, adverse-event assessment, imaging follow-up, and later-line treatment planning. The transition could accelerate as oral targeted regimens and maintenance-oriented immunotherapy combinations become more widely adopted following the maturation of ongoing trials. Consequently, the market is expected to develop a two-step care model, in which hospitals manage the initial high-acuity treatment episode while specialty clinics increasingly support recurring monitoring and maintenance activities.

Geography Analysis

North America Adrenocortical Carcinoma Treatment Market

North America is projected to hold the largest share of the adrenocortical carcinoma treatment market, accounting for 43.38% in 2025. The region benefits from strong referral networks, rare-disease reimbursement support, and a high concentration of specialized cancer centers. The United States remains central to evidence generation, with the National Cancer Institute expected to launch a Phase 2 trial of cabozantinib plus cemiplimab in February 2026. The planned 48-patient cohort will include adolescents and adults. Canada supports treatment continuity through updated product guidance, while the December 2024 revision to the Lysodren monograph is expected to align national labeling with more recent safety and drug-interaction standards. In revenue terms, North America is projected to account for 43.38% of the adrenocortical carcinoma treatment market size in 2025, reflecting more established clinical access and reimbursement systems than in most other regions.

Europe Adrenocortical Carcinoma Treatment Market

Europe is projected to remain the second-largest regional market, led by Germany, France, the United Kingdom, and Italy. The region continues to contribute substantially to foundational treatment evidence, as major European groups have helped establish standards for surgery, adjuvant treatment, and systemic care. Lysodren maintains full European Medicines Agency (EMA) marketing authorization for advanced, unresectable, metastatic, or relapsed adrenocortical carcinoma (ACC). The product information update scheduled for April 2025 is expected to preserve its position as the default systemic treatment option across Europe. Europe also continues to support clinical trial activity and multidisciplinary treatment planning, concentrating commercial activity in academic referral hospitals.

APAC Adrenocortical Carcinoma Treatment Market

Asia-Pacific is projected to record the fastest regional CAGR of 7.46% through 2031, driven by expanding cancer infrastructure and rising incidental detection through broader imaging use. China has gained greater visibility in clinical evidence following the Phase 2 study of camrelizumab plus apatinib, which reported stronger activity than most single-agent immunotherapy data in previously treated ACC. South Korea also contributes through the ACCOMPLISH trial of pembrolizumab plus lenvatinib, which remains active in post-platinum disease and is expected to complete its primary evaluation in 2027. Japan and India support the regional outlook through expanding oncology capacity rather than a high volume of branded ACC-specific commercial assets.